iCare ILLUME screening solution for diabetic retinopathy

Why is screening for diabetic retinopathy important?

The current estimates state that one in five diabetics have diabetic retinopathy (DR). Without screening, DR often goes undiagnosed until vision changes, sometimes irreversible, occur in the later stages of the disease.

Diabetics themselves often have no subjective symptoms of DR, in part because initial signs in the early stages of the disease may only be intermittent. To slow the progression of DR, lifestyle and diet changes are important but the primary motivation for screening is that there are now very effective treatment options for preventing or significantly slowing vision loss. The rate of DR progression may be rapid, so timely intervention is vital.

Why use artificial intelligence in screening?

  • Artificial intelligence (AI) provides efficient processing for higher throughput
  • AI detects early signs of retinal pathologies instantly and classifies the results according to severity
  • AI allows ophthalmologists to focus on patients who are most in need of specialized care
  • Our AI partner Thirona B.V. provides results that match the level of a professional human grader

Using the iCare DRSplus TrueColor fundus imaging system together with RetCAD AI, the iCare ILLUME solution has been shown to have excellent sensitivity and specificity for the detection of referable DR. Studies have shown that the AI behind iCare ILLUME to be at least as good as human reading for finding referable DR. Furthermore, iCare ILLUME has the advantage of offering a consistent diagnostic service quality, available at all times.

In real-world situations the use of AI has been shown to significantly improve the detection of sight-threatening DR. The iCare ILLUME is a secure and easy-to-use solution that adds the power of AI diagnostics to iCare DRSplus confocal fundus imaging systems.

Download the whitepaper here